ARTICLE AD BOX
New Delhi: The discussion around Oral Rehydration Salts (ORS), electrolyte drinks, and product labelling in India continues to evolve, with legal proceedings, medical observations, and regulatory developments shaping the issue. The matter is also linked to an ongoing case in the Delhi High Court involving FDC Limited and Johnson & Johnson along with associated entities.
As per the official court order dated March 27, 2026, accessed via, the case has been listed before another roster bench. The order indicates that the matter is still under process and no final judgment has been delivered so far.
At the centre of the broader discussion is ORS, a clinically formulated solution recommended by the World Health Organization for treating dehydration caused by diarrhoea. Health experts widely consider ORS an essential medical intervention, particularly for children, due to its scientifically balanced composition.
According to, Hyderabad-based paediatrician Dr. Sivaranjani Santosh has, over several years, raised awareness about how certain electrolyte drinks are labelled and understood by consumers. Her observations have focused on the importance of clear differentiation between medically recommended ORS and other beverages available in the market.
According to the reports, historically, some ready-to-drink electrolyte products have been packaged in ways that may appear similar to ORS. Medical professionals cited in the report have highlighted that such similarities can sometimes lead to confusion among consumers, especially in situations where ORS is required for treatment.
In October 2025, the Food Safety and Standards Authority of India (FSSAI) introduced stricter guidelines related to ORS labelling. Following these changes, Kenvue, a consumer health company that was earlier part of Johnson & Johnson, rebranded its electrolyte drink from ORSL to ERZL. As per statements cited in Frontline, the company maintained that the rebranding was done in line with regulatory requirements.
At the same time, some public health advocates have continued to call for greater clarity in naming and presentation of such products. Dr. Sivaranjani Santosh, in statements quoted across reports, has expressed the view that clear distinction is important so that consumers can easily identify medically recommended ORS when needed.
The situation has also seen responses from the medical community. As reported by, multiple medical associations have expressed support for discussions around patient safety and the role of doctors in raising awareness. Organizations such as the Federation of All India Medical Association (FAIMA) have stated that highlighting such concerns is part of a doctor’s professional responsibility.
Separately, the ongoing court case filed by FDC Limited relates to a branding dispute, where the company has approached the Delhi High Court. Court records confirm that the matter is currently at a procedural stage, with further hearings expected.
Recent discussions and reports on social media, as referenced in multiple reports, have also pointed to claims regarding packaging and relabelling practices. However, these observations remain subject to verification by relevant authorities, and no official confirmation has been issued so far by regulators.
English (US) ·